Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo

Updates

Search
All Resources
Press Releases
Videos

Dr. Lee Kaplan MD, Director of Dartmouth Health’s Weight and Wellness Center, suggests new MoAs to tackle the GI intolerance of GLP-1s and highlights Vial’s INHBE siRNA program as a promising target to compliment and potentially enhance current treatments.

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, emphasizes how Vial’s INHBE siRNA directly impacts the function of adipose tissue to better address cellular hypertrophy and inflammation.

Obesity expert and researcher, Dr. Lawrence Cheskin MD, discusses how targeting adipose tissue is critical for treating obesity, positioning INHBE siRNA as a promising target to drive quality fat loss.

Dr. Scott Kahan, Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies.

Dr. Lee Kaplan, Director at Dartmouth Health’s Weight and Wellness Center, points to the myostatin/activin pathway as a promising target.

Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research on the next breakthroughs in obesity treatment.

Vial’s INHBE siRNA is designed to block Activin E signaling and increase lipolysis for fat-selective weight loss selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Dr. Jason Fung: Treating obesity means more than weight loss – it’s about correcting metabolic disease. Vial’s INHBE siRNA can help obese and overweight populations avoid major health issues.

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

Load More

Dr. Lee Kaplan MD, Director of Dartmouth Health’s Weight and Wellness Center, suggests new MoAs to tackle the GI intolerance of GLP-1s and highlights Vial’s INHBE siRNA program as a promising target to compliment and potentially enhance current treatments.

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, emphasizes how Vial’s INHBE siRNA directly impacts the function of adipose tissue to better address cellular hypertrophy and inflammation.

Obesity expert and researcher, Dr. Lawrence Cheskin MD, discusses how targeting adipose tissue is critical for treating obesity, positioning INHBE siRNA as a promising target to drive quality fat loss.

Dr. Scott Kahan, Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies.

Dr. Lee Kaplan, Director at Dartmouth Health’s Weight and Wellness Center, points to the myostatin/activin pathway as a promising target.

Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research on the next breakthroughs in obesity treatment.

Vial’s INHBE siRNA is designed to block Activin E signaling and increase lipolysis for fat-selective weight loss selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Dr. Jason Fung: Treating obesity means more than weight loss – it’s about correcting metabolic disease. Vial’s INHBE siRNA can help obese and overweight populations avoid major health issues.

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.